Azithromycin is a macrolide antibiotic, specifically the first member of a subclass called azalides. It’s one of the most commonly prescribed antibiotics in the world, used to treat a wide range of bacterial infections from sinus infections to pneumonia to certain sexually transmitted infections. Its unusually long half-life in the body is the reason you can take it for just three to five days instead of the seven to ten days typical of many other antibiotics.
Macrolide Class and Azalide Subclass
Macrolides are a family of antibiotics that includes erythromycin, clarithromycin, and azithromycin. They share a common structural feature: a large ring-shaped molecule called a lactone ring. Erythromycin, the original macrolide, has a 14-membered ring. Azithromycin was derived from erythromycin by inserting a nitrogen atom into that ring, expanding it to 15 members. This single structural change was significant enough to create a new subclass, the azalides, and it gave azithromycin several practical advantages over its parent drug.
The modified structure makes azithromycin more stable in stomach acid, which means better absorption when taken by mouth. It also concentrates more effectively inside cells and tissues, which is why drug levels in infected tissue can be many times higher than levels in the blood.
How Azithromycin Kills Bacteria
Azithromycin works by shutting down a bacterium’s ability to make proteins. Bacteria depend on molecular machines called ribosomes to build the proteins they need to grow and reproduce. Azithromycin binds to a specific spot on the larger half of the ribosome, lodging itself in a narrow exit tunnel that newly made proteins pass through. By physically blocking this tunnel, the drug prevents the bacterium from assembling functional proteins. Without new proteins, the bacteria can’t multiply and are eventually cleared by your immune system.
This mechanism is generally bacteriostatic, meaning it stops bacteria from growing rather than directly killing them. At higher concentrations in tissues, though, it can have a bactericidal effect against certain organisms.
What Infections It Treats
Azithromycin covers a broad range of bacteria, including many gram-positive organisms (like strep and staph), several gram-negative bacteria, and a group called “atypical” bacteria that other common antibiotics miss entirely. That atypical coverage is one of the main reasons doctors reach for it.
Its FDA-approved uses in adults include:
- Respiratory infections: community-acquired pneumonia, acute bacterial sinusitis, flare-ups of chronic bronchitis, and strep throat (as a backup option for people who can’t take first-line drugs like penicillin)
- Sexually transmitted infections: chlamydia, gonorrhea-related urethritis and cervicitis, and chancroid
- Skin infections: uncomplicated infections caused by staph or strep bacteria
In children over six months, it’s commonly prescribed for ear infections and pneumonia. It’s also used off-label for traveler’s diarrhea, whooping cough, and infections caused by bacteria like Bartonella (the organism behind cat scratch disease).
Its ability to target atypical bacteria, particularly Mycoplasma and Chlamydophila, makes it especially useful for “walking pneumonia” and other respiratory infections where the exact cause hasn’t been identified.
Why a Short Course Works
One of azithromycin’s most distinctive features is its extremely long half-life. After a single oral dose, the drug stays active in the body with an average terminal half-life of 68 hours, nearly three days. Most antibiotics have half-lives measured in hours, not days.
This happens because azithromycin is rapidly absorbed from the bloodstream into tissues, particularly into white blood cells that travel to sites of infection. The drug then slowly releases back from those tissues over days. The result is that therapeutic levels persist at the infection site long after you’ve taken your last pill. This is why the classic “Z-Pack” (a five-day course) continues working for several days after you finish it, effectively providing about ten days of antibacterial activity from five days of pills.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent side effects. In clinical trials of the standard multi-dose regimen, 4 to 5% of adults experienced diarrhea or loose stools, about 3% had nausea, and 2 to 3% reported abdominal pain. Higher single doses cause more GI trouble: a single 2-gram dose (used for certain STIs) produced nausea in 18% of patients and diarrhea in 14%.
These side effects are generally mild and resolve on their own. Azithromycin tends to be better tolerated than erythromycin, which is notorious for causing stomach upset, largely because of the structural modifications that created the azalide subclass.
Heart Rhythm Risk
The FDA has issued a safety warning that azithromycin can cause abnormal changes in the heart’s electrical activity, potentially leading to a dangerous irregular rhythm called torsades de pointes. This risk is rare in the general population but becomes more relevant for certain groups: people with pre-existing heart rhythm disorders, those with very slow heart rates, people with low potassium or magnesium levels, and anyone already taking other medications that affect the heart’s electrical timing. Older adults and people with heart disease are also more susceptible.
Growing Resistance Concerns
Macrolide resistance is an increasing problem, particularly among Streptococcus pneumoniae, one of the most common causes of pneumonia, sinus infections, and ear infections. In some regions, 20 to 30% of pneumococcal strains are already resistant to azithromycin. Studies of mass drug administration programs in sub-Saharan Africa have shown that widespread azithromycin use can drive resistance rates even higher, with macrolide resistance climbing from about 22% at baseline to 32% three and a half years later. Perhaps more concerning, macrolide use appears to co-select for resistance to other antibiotic classes, including penicillins, raising the possibility of multidrug-resistant strains that are harder to treat with any available option.
This resistance trend is one reason azithromycin is listed as a second-line option for strep throat rather than a first choice. For respiratory infections where the cause is unknown, many guidelines still recommend it because of its atypical bacteria coverage, but the growing resistance among common pathogens means its reliability isn’t what it once was.